Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00035256 · ClinicalTrials.gov registry record · Phase 4
Sequential Use of Teriparatide and Raloxifene HCl in the Treatment of Postmenopausal Women With Osteoporosis
A Phase 4 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 4
- Development phase
- 330
- Enrollment target
NCT00035256 is a Phase 4 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 330 participants.
The verdict
NCT00035256, a Phase 4 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 330 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether the increase in spine bone mineral density that has been generally observed in previous clinical studies involving the study drug can be maintained or even increased if followed with raloxifene HCl. All qualifying study participants will receive the study drug followed by treatment with raloxifene HCl or placebo. All study participants will receive raloxifene HCl in the third phase of the study.
Interventions
- DRUG placebo
- DRUG teriparatide
- DRUG raloxifene HCl
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 330 participants |
| Start Date | 2001-10 |
| Est. Completion | 2005-07 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00035256
The ClinicalTrials.gov registry entry for NCT00035256 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 330 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which placebo is the first listed.
NCT00035256 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00035256 about?
NCT00035256 is a clinical study titled "Sequential Use of Teriparatide and Raloxifene HCl in the Treatment of Postmenopausal Women With Osteoporosis". The purpose of this study is to determine whether the increase in spine bone mineral density that has been generally observed in previous clinical studies involving the study drug can be maintained or even increased if followed with raloxifene HCl. All qualifying study participants will receive the ...
What is the current status of trial NCT00035256?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 330 participants. The study started on 2001-10. Estimated completion is 2005-07.
What interventions are being tested in trial NCT00035256?
The interventions under investigation include: placebo (DRUG), teriparatide (DRUG), raloxifene HCl (DRUG).
Who is sponsoring clinical trial NCT00035256?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.